Industry estimates suggest unit sales of semaglutide could increase two to three times within a full month of availability, although value growth remains lower due to pricing pressures.
With insulin scale, US launches, GLP-1 ambitions and an oncology pipeline, the company is building where others are not looking.
Acquisition of 58.4% stake marks eastern expansion; asset offers scope to scale to 1,000 beds
Lilly's FDA approval of Foundayo puts it in direct competition with Novo Nordisk's oral Wegovy. Back home, Indian companies are lining up their own GLP-1 bets from generics to novel molecules
Under Sharvil Patel, Zydus Lifesciences' pipeline reflects a strategy built on sustained innovation.
Move aims to cushion pharma and medical device makers from rising input costs and supply disruptions
Move follows patent expiry and intensifying competition, with monthly therapy costs now starting at Rs 3,999.
As cheaper versions enter the market and competition increases, the government is stepping in to regulate how these drugs are prescribed, sold and promoted
Anurag Choudhary has expanded Himadri Speciality Chemical beyond its traditional carbon business into specialty chemicals and advanced materials.
Novo Nordisk India has cut prices of its semaglutide therapies Ozempic and Wegovy by up to 48% at the starting dose, as competition intensifies following patent expiry and the entry of generics. The r...
Over 1 Crore Voters Cast Ballots As Assam, Kerala And Puducherry Seal Assembly Poll Fate
Why Islamabad Is Hosting Crucial U.S.-Iran Talks That Could Reshape West Asia And Global Geopolitics
West Asia Crisis Exposed India’s Energy Vulnerabilities, Says Petroleum Secretary Neeraj Mittal
How BJP Rose From Fringe Force To Mamata Banerjee’s Biggest Threat In West Bengal Politics
Tata Sons IPO Debate Deepens: Board Split, Trusts Oppose As Listing Pressure Builds
